ArticleTherapeutic advances in hematology2012

Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.

Claire Harrison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.